BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms- Americans generally like wolves − except when we’re reminded of our politics
- 6 Natural products High In Vitamins,Which One Do You Like to Eat
- What to know as New York City nurses strike for a 3rd day
- Israeli forces kill one person in series of attacks on southern Lebanon
- Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- Zelensky warns of imminent massive Russian attack on Ukraine
- Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
